This important preprint (LINK AT THE END OF ARTICLE) needs to hit alternative and mainstream media now.
The Study:
Background: Previously, we demonstrated that ivermectin use as prophylaxis for COVID-19 was associated with reductions in COVID-19 infection, hospitalization, and mortality rates, and in the risk of dying from COVID-19, irrespective of regularity and accumulated use of ivermectin, in an observational, prospectively obtained data from a strictly controlled city-wide program in a city in Southern Brazil (Itajaí, SC, Brazil) of of medically-based, optional use of ivermectin as prophylaxis for COVID-19.
In this study, our objective was to explore the data obtained from the program to evaluate whether the level of regularity of ivermectin use impacted in the reductions in these outcomes, aiming to determine if ivermectin showed a progressive dose-, regularity-response in terms of protection from COVID-19 and COVID-19 related outcomes.
Materials and methods: This is a prospective observational study of the program mention above, that used ivermectin at a dose of 0.2mg/kg/day for two consecutive days, every 15 days. We obtained and analyzed the data regarding the accumulated dose of ivermectin use, in addition to age and co-morbidities, to analyze the patterns of reduction of COVID-19 infection, hospitalization, and mortality rates, and risk of dying from COVID-19, according to the regularity and amount of ivermectin used in a 5-month period.
Following definitions of regularity, we considered as strictly regular subjects that used at least 180mg of ivermectin (180mg = 30 tablets), and as sporadic users subjects that used 60mg (= 10 tablets) or less during the 5-month period.
Comparisons between subjects that did not use ivermectin and these two levels of regularity of ivermectin use were performed. Analysis of the intermediate levels of ivermectin use are present in the supplement appendix of this study. To analyze hospitalization and mortality rates, we utilized the database of COVID-19 infections of all participants, from Itajaí and outside. To analyze COVID-19 infection rate and risk of dying from COVID-19 we utilized the Itajaí city database.
Propensity score matching (PSM) was employed, followed by multivariate adjusted analysis for residual differences (doubly adjusted analysis).
Results:
- Of the 7,345 cases of COVID-19, 3,034 occurred in non-users, 1,627 in sporadic users, and 289 in strict users, while the remaining cases occurred in the intermediate levels of ivermectin use. Strict users were older (p < 0.0001) and non-significant higher prevalence of type 2 diabetes and hypertension.
- COVID-19 infection rate was 39% lower among strict users [4.03% infection rate; ( p < 0.0001] than in non-users (6.64% infection rate), and non-significant 11% reduction compared to sporadic users (4.54% infection rate) (n = 1,627 in each group; RR, 0.89; 95%CI 0.76 – 1.03; p = 0.11).
- Hospitalization rate was reduced by 100% in strict users, compared to non-users and to sporadic users, both before and after Propensity score matching ( p < 0.0001).
- After Propensity score matching, hospitalization rate was 35% lower among sporadic users than non-users (RR, 0.65; 95%CI, 0.44 – 0.70; p = 0.03).
- In propensity score matched groups, multivariate-adjusted mortality rate was 90% lower in strict users compared to non-users (p = 0.003) and 79% lower than in sporadic users (p = 0.05), while sporadic users had a 37% reduction in mortality rate compared to non-users (p = 0.043).
- Risk of dying from COVID-19 was 86% lower among strict users than non-users (p = 0.006) and marginally significant, 72% lower than sporadic users (p = 0.083), while sporadic users had a 51% reduction compared to non-users (p = 0.001).
Conclusion: Non-use of ivermectin was associated with a 10-times increase in mortality risk and 7-times increased risk of dying from COVID-19, compared to strictly regular use of ivermectin in a prospectively collected, strictly controlled population.
A progressive dose-response pattern was observed between level of ivermectin use and level of protection from COVID-19 related outcomes and consistent across different levels of ivermectin use.
The results of this study clearly demonstrate that prophylactic use of ivermectin must be initiated immediately for people in high risk categories in the United States and worldwide.
This includes individuals with one or more co-morbidities and the middle aged/elderly.
Our “design-to-fail” government funded clinical trials for early treatment and governmental obstructionism regarding life saving treatments to patients must end now.
Subscribe to Galileyo
Galileyo is a new Information Distribution Platform that gathers uncensored information from our proprietary global information sources and delivers that information to you, regardless of the situation on the ground, via global Satellite Phone Networks.
Subscribe to Galileyo
Support my work
If you follow my website StrangeSounds.org, you already know that my site has been banned from ALL ADS NETWORKS! So now I really count on you and your donations to keep Strange Sounds up and running! Support my work and family. Thank you for your help!
Paypal Donation Link
If you use Amazon, you can also use our link below, to enable us getting a small affiliate revenue. Thanks again!
Support Us With Amazon
Or if you enjoy natural health products, I recommend Natural Health Source:
Support Us With Natural Health Source
Finally, you can also subscribe to this blog to get more amazing news curated just for you right in your inbox on a daily basis.
Subscribe to my Newsletter
You should really subscribe to QFiles. You will get very interesting information about strange events around the world.
Where can we buy Ivermectin?
How many mg of ivermectin do you recommend we take daily. And can we buy it direct somewhere perhaps on your site